about
Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age GroupsApproach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentaryEmerging uses of patient generated health data in clinical research.NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.Conditioning regimens for hematopoietic cell transplantation: one size does not fit allSafety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia.Impact of donor age on outcome after allogeneic hematopoietic cell transplantation.Thymic T-cell development in allogeneic stem cell transplantationCurrent status of allogeneic hematopoietic cell transplantation for MDS.Allogeneic hematopoietic cell transplantation for MDS: for whom, when and how?Myelodysplastic syndromes: clinical practice guidelines in oncology.Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: current status.Allogeneic transplantation in the UK: an aggregation of marginal gains?Health-Related Quality of Life among Older Related Hematopoietic Stem Cell Donors (>60 Years) Is Equivalent to That of Younger Related Donors (18 to 60 Years): A Related Donor Safety Study.Effects of physical exercise on survival after allogeneic stem cell transplantation.Population-Based Analysis of Hematologic Malignancy Referrals to a Comprehensive Cancer Center, Referrals for Blood and Marrow Transplantation, and Participation in Clinical Trial, Survey, and Biospecimen Research by Race.Retinoid differentiation therapy for common types of acute myeloid leukemia.Myeloablative hematopoietic stem cell transplantation improves survival but is not curative in a pre-clinical model of myelodysplastic syndrome.Indications for and current results with allogeneic hematopoietic cell transplantation in patients with myelofibrosis.The impact of CD34+ cell dose on engraftment after SCTs: personalized estimates based on mathematical modeling.Impact of low-dose TBI on outcomes of reduced intensity conditioning allogeneic hematopoietic stem cell transplantation for AML.Cardiopulmonary fitness in patients undergoing hematopoietic SCT: a pilot study.US oncology-wide incidence, duration, costs and deaths from chemoradiation mucositis and antimucositis therapy benefits.Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect.Treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia with imatinib combined with a paediatric-based protocol.Outcomes of adults with active or progressive hematological malignancies at the time of allo-SCT: a survey from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
P2860
Q26786893-E7033ABE-EFC2-491C-8EDE-E1844C825F41Q28088365-924F2558-2F43-4104-BD46-AAFC8D7139EEQ30854718-59FC307F-3811-48EE-95A8-3FF65E7B3948Q33393647-AC9F867A-D745-450A-BBB1-E726FEFF19FCQ33917170-6C2449B1-3FE4-49D9-B290-4055D26BAF4FQ34060237-CB526718-6D3D-48F3-ADBF-B50ABEB6B92FQ34859147-C6F2570A-CF52-48BE-9F25-AEB827CA5E2CQ35083246-E808A2CE-41D4-4BFB-A232-C8351A53A8FFQ36063049-EC395329-6CE0-4DD9-8F89-31B018822EF5Q36431041-3FC191A7-95CD-48A0-AB49-ACBB6131D199Q37723847-8C52CE0D-9260-46A3-A264-0ADCD071BA54Q37964938-176E129A-53BF-4C98-A29A-F3191231AA7BQ38124363-ECB3AE2B-75C8-4CAC-A785-1513E0B8B6CFQ39280156-D9F7AC1E-045E-4B17-B641-CBC4DECA0332Q40850367-3290AEAB-AE65-4CD9-B273-4FDBD65A4137Q41032965-CFFA0F5E-0D2B-41BF-A299-0C677BD88B1BQ41723841-3F62F765-58FD-421A-941F-8BAC93F3A0C8Q42025658-E487EAD6-330E-47CE-A89A-E7C7E1AAB0AFQ42840838-EA52E33D-DA02-4D3A-8F8B-6E5DE08BA483Q43417842-11EF0E48-A949-46D8-AD67-D69C905190E2Q43616985-CDC72412-4FA3-43C1-BC48-4DF94F09829DQ45143552-12879CDB-7AC4-49CD-8534-FA5AA3A7CD1BQ47691393-721558D2-98C5-4713-8455-AF2528E6B9BCQ50790069-2216E97D-3131-42EE-91C8-7167066DA6B9Q54507760-88E54B08-E717-46DE-A4C4-74736C74DDCCQ54509279-06D88FA4-45BD-4499-BE86-1A30379DD65A
P2860
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Who is fit for allogeneic transplantation?
@ast
Who is fit for allogeneic transplantation?
@en
type
label
Who is fit for allogeneic transplantation?
@ast
Who is fit for allogeneic transplantation?
@en
prefLabel
Who is fit for allogeneic transplantation?
@ast
Who is fit for allogeneic transplantation?
@en
P2860
P1433
P1476
Who is fit for allogeneic transplantation?
@en
P2860
P304
P356
10.1182/BLOOD-2010-07-259358
P407
P577
2010-08-11T00:00:00Z